How Should Clinicians Interpret Conflicting Cost-effectiveness Analyses for the Treatment of Lymphoma Across Nations and Payer Models?

Overview

Journal Leuk Lymphoma

Specialties Hematology
Oncology

Date 2020 Nov 4

PMID 33143518

Authors

R Andrew Harkins

Christopher R Flowers

Affiliations

Soon will be listed here.

References

Hicks L, Bering H, Carson K, Kleinerman J, Kukreti V, Ma A . The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question. Blood. 2013; 122(24):3879-83. DOI: 10.1182/blood-2013-07-518423. View

Mariotto A, Yabroff K, Shao Y, Feuer E, Brown M . Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011; 103(2):117-28. PMC: 3107566. DOI: 10.1093/jnci/djq495. View

Gandjour A . Willingness to pay for new medicines: a step towards narrowing the gap between NICE and IQWiG. BMC Health Serv Res. 2020; 20(1):343. PMC: 7178559. DOI: 10.1186/s12913-020-5050-9. View

Fojo T, Lo A . Price, value, and the cost of cancer drugs. Lancet Oncol. 2016; 17(1):3-5. DOI: 10.1016/S1470-2045(15)00564-1. View

van Harten W, Wind A, de Paoli P, Saghatchian M, Oberst S . Actual costs of cancer drugs in 15 European countries. Lancet Oncol. 2015; 17(1):18-20. DOI: 10.1016/S1470-2045(15)00486-6. View

Goldstein D, Chen Q, Ayer T, Chan K, Virik K, Hammerman A . Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis. Oncologist. 2017; 22(6):694-699. PMC: 5469597. DOI: 10.1634/theoncologist.2016-0455. View

Paulden M . Recent amendments to NICE's value-based assessment of health technologies: implicitly inequitable?. Expert Rev Pharmacoecon Outcomes Res. 2017; 17(3):239-242. DOI: 10.1080/14737167.2017.1330152. View

Harkins R, Patel S, Flowers C . Cost-effectiveness of New Targeted Agents in the Treatment of Chronic Lymphocytic Leukemia. Cancer J. 2019; 25(6):418-427. PMC: 7141587. DOI: 10.1097/PPO.0000000000000411. View

Patel K, Isufi I, Kothari S, Foss F, Huntington S . Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2020; 61(14):3387-3394. DOI: 10.1080/10428194.2020.1808208. View

10.

Vogler S, Vitry A, Babar Z . Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study. Lancet Oncol. 2015; 17(1):39-47. DOI: 10.1016/S1470-2045(15)00449-0. View

11.

Brown M, Lipscomb J, Snyder C . The burden of illness of cancer: economic cost and quality of life. Annu Rev Public Health. 2001; 22:91-113. DOI: 10.1146/annurev.publhealth.22.1.91. View

12.

Goldstein D, Chen Q, Ayer T, Howard D, Lipscomb J, Ramalingam S . Necitumumab in Metastatic Squamous Cell Lung Cancer: Establishing a Value-Based Cost. JAMA Oncol. 2015; 1(9):1293-300. DOI: 10.1001/jamaoncol.2015.3316. View

13.

Schnipper L, Davidson N, Wollins D, Blayney D, Dicker A, Ganz P . Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. J Clin Oncol. 2016; 34(24):2925-34. DOI: 10.1200/JCO.2016.68.2518. View

14.

Neumann P, Cohen J, Weinstein M . Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014; 371(9):796-7. DOI: 10.1056/NEJMp1405158. View

15.

De Block M . The difficulty of comparing drug prices between countries. Lancet Oncol. 2016; 17(4):e125. DOI: 10.1016/S1470-2045(16)00176-5. View

16.

Iunes R, Uribe M, Torres J, Garcia M, Dias C, Alvares-Teodoro J . Confidentiality agreements: a challenge in market regulation. Int J Equity Health. 2019; 18(1):11. PMC: 6545740. DOI: 10.1186/s12939-019-0916-3. View

17.

Harkins R, Patel S, Flowers C . Cost burden of diffuse large B-cell lymphoma. Expert Rev Pharmacoecon Outcomes Res. 2019; 19(6):645-661. PMC: 6930962. DOI: 10.1080/14737167.2019.1680288. View

18.

Hilal T, Betcher J, Leis J . Economic Impact of Oral Therapies for Chronic Lymphocytic Leukemia-the Burden of Novelty. Curr Hematol Malig Rep. 2018; 13(4):237-243. DOI: 10.1007/s11899-018-0461-y. View

19.

Sehn L, Herrera A, Flowers C, Kamdar M, McMillan A, Hertzberg M . Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2019; 38(2):155-165. PMC: 7032881. DOI: 10.1200/JCO.19.00172. View